LONDON (Alliance News) - Pharmaceuticals giant GlaxoSmithKline PLC on Wednesday said its ViiV Healthcare HIV unit has received data from the STRIIVING study on its Triumeq treatment, which showed switching to a once-daily dose of the drug maintained HIV viral suppression in patients.
ViiV said the Phase IIIb/IV study, studying the efficacy, safety and tolerability of switching from an antiretroviral therapy to the once-daily, fixed-dose dolutegravir-based Triumeq, met its primary endpoint of showing patients switching to the once-daily dose did not show any signs of decreased viral suppression.
ViiV also said the patient satisfaction score for those switching to the once-daily dose was significantly higher compared to their previous regimen.
"For clinicians, choosing among antiretroviral therapies now involves balancing efficacy with factors such as tolerability, dosing, ability to use with other medications, and resistance profile. These data support the use of once-daily abacavir/dolutegravir/lamivudine as a treatment option in the switch setting for appropriate patients," said John Pottage, managing director, chief scientific and medical officer at ViiV.
Shares in Glaxo were up 1.0% on Wednesday morning to 1,259.00 pence.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.